おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Zentalis Pharmaceuticals
company
About
Zentalis is a pharmaceutical company focused on developing clinical therapeutics for cancer patients.
- 101 - 250
Highlights
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $25M
- Industries
- Biopharma,Biotechnology,Pharmaceutical
- Founded date
- Dec 1, 2014
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental biological pathways in cancer. It was founded 2014 and headquartered in New York, United States.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$25M
Zentalis Pharmaceuticals has raised a total of
$25M
in funding over 2 rounds. Their latest funding was raised on
Apr 27, 2022 from a Post-IPO Equity round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Apr 27, 2022 | Post-IPO Equity | $25M | 1 |
Pfizer
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
Zentalis Pharmaceuticals is funded by 1 investors.
Pfizer
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Pfizer
|
Yes | Post-IPO Equity |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
